Lipocine
LPCN
LPCN
30 hedge funds and large institutions have $3.7M invested in Lipocine in 2018 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more ownership
Funds ownership: →
36% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 11
57% less call options, than puts
Call options by funds: $16K | Put options by funds: $37K
Holders
30
Holding in Top 10
–
Calls
$16K
Puts
$37K
Top Buyers
| 1 | +$930K | |
| 2 | +$84K | |
| 3 | +$65K | |
| 4 |
JPMorgan Chase & Co
New York
|
+$50K |
| 5 |
VF
Virtu Financial
New York
|
+$33K |
Top Sellers
| 1 | -$92K | |
| 2 | -$57K | |
| 3 | -$51.3K | |
| 4 |
Bank of New York Mellon
New York
|
-$35.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$17.5K |